Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.17
HOLX's Cash to Debt is ranked lower than
51% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. HOLX: 0.17 )
HOLX' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: 0.17

Equity to Asset 0.25
HOLX's Equity to Asset is ranked lower than
51% of the 275 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. HOLX: 0.25 )
HOLX' s 10-Year Equity to Asset Range
Min: 0.22   Max: 0.88
Current: 0.25

0.22
0.88
Interest Coverage 1.27
HOLX's Interest Coverage is ranked lower than
56% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.42 vs. HOLX: 1.27 )
HOLX' s 10-Year Interest Coverage Range
Min: 0.55   Max: 9999.99
Current: 1.27

0.55
9999.99
F-Score: 7
Z-Score: 0.64
M-Score: -2.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 11.05
HOLX's Operating margin (%) is ranked higher than
78% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. HOLX: 11.05 )
HOLX' s 10-Year Operating margin (%) Range
Min: -123.18   Max: 20.99
Current: 11.05

-123.18
20.99
Net-margin (%) 0.68
HOLX's Net-margin (%) is ranked higher than
65% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.97 vs. HOLX: 0.68 )
HOLX' s 10-Year Net-margin (%) Range
Min: -132.93   Max: 16.59
Current: 0.68

-132.93
16.59
ROE (%) 0.87
HOLX's ROE (%) is ranked higher than
64% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.15 vs. HOLX: 0.87 )
HOLX' s 10-Year ROE (%) Range
Min: -60.83   Max: 17.54
Current: 0.87

-60.83
17.54
ROA (%) 0.20
HOLX's ROA (%) is ranked higher than
65% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. HOLX: 0.20 )
HOLX' s 10-Year ROA (%) Range
Min: -31.48   Max: 14.52
Current: 0.2

-31.48
14.52
ROC (Joel Greenblatt) (%) 36.51
HOLX's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. HOLX: 36.51 )
HOLX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -370.53   Max: 99.3
Current: 36.51

-370.53
99.3
Revenue Growth (%) 10.30
HOLX's Revenue Growth (%) is ranked higher than
84% of the 261 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. HOLX: 10.30 )
HOLX' s 10-Year Revenue Growth (%) Range
Min: -7.9   Max: 35.9
Current: 10.3

-7.9
35.9
EBITDA Growth (%) 5.00
HOLX's EBITDA Growth (%) is ranked higher than
72% of the 219 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. HOLX: 5.00 )
HOLX' s 10-Year EBITDA Growth (%) Range
Min: -5.1   Max: 90.5
Current: 5

-5.1
90.5
EPS Growth (%) -53.30
HOLX's EPS Growth (%) is ranked lower than
52% of the 218 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. HOLX: -53.30 )
HOLX' s 10-Year EPS Growth (%) Range
Min: -68.1   Max: 369.3
Current: -53.3

-68.1
369.3
» HOLX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

HOLX Guru Trades in Q4 2013

Carl Icahn 34,154,879 sh (New)
Joel Greenblatt 156,851 sh (New)
Vanguard Health Care Fund 7,379,300 sh (+71.43%)
Paul Tudor Jones 375,000 sh (+50%)
Prem Watsa 20,000 sh (unchged)
Jean-Marie Eveillard 17,000 sh (unchged)
Ken Fisher 143,200 sh (unchged)
Pioneer Investments Sold Out
Manning & Napier Advisors, Inc 564,735 sh (-2.71%)
Irving Kahn 1,349,570 sh (-12.92%)
Jim Simons 366,485 sh (-40.84%)
Steven Cohen 20,460 sh (-98%)
» More
Q1 2014

HOLX Guru Trades in Q1 2014

Murray Stahl 36,555 sh (New)
Steven Cohen 191,791 sh (+837.39%)
Irving Kahn 1,556,979 sh (+15.37%)
Prem Watsa 20,000 sh (unchged)
Vanguard Health Care Fund 7,379,300 sh (unchged)
Carl Icahn 34,154,879 sh (unchged)
Jean-Marie Eveillard 17,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Ken Fisher 129,100 sh (-9.85%)
Joel Greenblatt 100,601 sh (-35.86%)
» More
Q2 2014

HOLX Guru Trades in Q2 2014

Jim Simons 949,418 sh (New)
Joel Greenblatt 205,907 sh (+104.68%)
Vanguard Health Care Fund 7,379,300 sh (unchged)
Prem Watsa 20,000 sh (unchged)
Carl Icahn 34,154,879 sh (unchged)
Ken Fisher 129,100 sh (unchged)
Jean-Marie Eveillard Sold Out
Irving Kahn 1,541,729 sh (-0.98%)
Murray Stahl 30,951 sh (-15.33%)
» More
Q3 2014

HOLX Guru Trades in Q3 2014

Paul Tudor Jones 660,469 sh (New)
Jim Simons 1,574,218 sh (+65.81%)
Murray Stahl 33,815 sh (+9.25%)
Ken Fisher 129,690 sh (+0.46%)
Prem Watsa 20,000 sh (unchged)
Carl Icahn 34,154,879 sh (unchged)
Vanguard Health Care Fund 7,379,300 sh (unchged)
Irving Kahn 1,541,159 sh (-0.04%)
Joel Greenblatt 16,119 sh (-92.17%)
» More
» Details

Insider Trades

Latest Guru Trades with HOLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Reduce -92.17%0.06%$24.14 - $26.28 $ 26.485%16119
Joel Greenblatt 2014-06-30 Add 104.68%0.03%$20.27 - $25.6 $ 26.4814%205907
Jean-Marie Eveillard 2014-06-30 Sold Out $20.27 - $25.6 $ 26.4814%0
Irving Kahn 2014-03-31 Add 15.37%0.64%$20.11 - $22.58 $ 26.4823%1556979
Joel Greenblatt 2014-03-31 Reduce -35.86%0.03%$20.11 - $22.58 $ 26.4823%100601
Carl Icahn 2013-12-31 New Buy2.5%$20.51 - $22.899 $ 26.4820%34154879
Irving Kahn 2013-12-31 Reduce -12.92%0.61%$20.51 - $22.899 $ 26.4820%1349570
Vanguard Health Care Fund 2013-12-31 Add 71.43%0.21%$20.51 - $22.899 $ 26.4820%7379300
Joel Greenblatt 2013-12-31 New Buy0.08%$20.51 - $22.899 $ 26.4820%156851
Ray Dalio 2013-09-30 Sold Out 0.01%$18.69 - $23 $ 26.4824%0
Vanguard Health Care Fund 2013-06-30 New Buy0.3%$19.04 - $22.82 $ 26.4827%4304500
Mariko Gordon 2013-06-30 Sold Out 0.02%$19.04 - $22.82 $ 26.4827%0
Ray Dalio 2013-06-30 New Buy0.01%$19.04 - $22.82 $ 26.4827%43800
Irving Kahn 2013-03-31 Add 2.41%0.12%$20.01 - $23.84 $ 26.4819%1562574
Ken Fisher 2013-03-31 Add 21.22%$20.01 - $23.84 $ 26.4819%133100
Joel Greenblatt 2012-09-30 Sold Out 0.09%$18.01 - $21.05 $ 26.4836%0
George Soros 2012-09-30 Sold Out 0.05%$18.01 - $21.05 $ 26.4836%0
Ken Fisher 2012-09-30 New Buy0.01%$18.01 - $21.05 $ 26.4836%93900
Joel Greenblatt 2012-06-30 New Buy0.09%$16.38 - $22.06 $ 26.4843%69842
George Soros 2012-06-30 New Buy0.05%$16.38 - $22.06 $ 26.4843%200000
Whitney Tilson 2012-03-31 Sold Out 0.92%$17.91 - $21.85 $ 26.4838%0
Whitney Tilson 2011-12-31 Add 14.44%0.12%$14.23 - $17.84 $ 26.4862%103000
George Soros 2011-12-31 Sold Out 0.0032%$14.23 - $17.84 $ 26.4862%0
Whitney Tilson 2011-09-30 New Buy0.5%$15.15 - $20.82 $ 26.4852%90000
George Soros 2011-09-30 Reduce -34.74%$15.15 - $20.82 $ 26.4852%12400
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Hologic Inc

Weekly CEO Buys Highlight: HOLX, EPB, CLMS, IDTI, BYI
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 464.60
HOLX's P/E(ttm) is ranked higher than
66% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.50 vs. HOLX: 464.60 )
HOLX' s 10-Year P/E(ttm) Range
Min: 25.24   Max: 465.09
Current: 464.6

25.24
465.09
P/B 3.60
HOLX's P/B is ranked higher than
68% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.51 vs. HOLX: 3.60 )
HOLX' s 10-Year P/B Range
Min: 0.59   Max: 10.61
Current: 3.6

0.59
10.61
P/S 2.90
HOLX's P/S is ranked higher than
70% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.92 vs. HOLX: 2.90 )
HOLX' s 10-Year P/S Range
Min: 1.47   Max: 7.73
Current: 2.9

1.47
7.73
PFCF 17.20
HOLX's PFCF is ranked higher than
95% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 719.57 vs. HOLX: 17.20 )
HOLX' s 10-Year PFCF Range
Min: 6.34   Max: 633.75
Current: 17.2

6.34
633.75
EV-to-EBIT 39.00
HOLX's EV-to-EBIT is ranked higher than
72% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.27 vs. HOLX: 39.00 )
HOLX' s 10-Year EV-to-EBIT Range
Min: -125.3   Max: 118
Current: 39

-125.3
118
Current Ratio 2.53
HOLX's Current Ratio is ranked higher than
68% of the 275 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. HOLX: 2.53 )
HOLX' s 10-Year Current Ratio Range
Min: 1.49   Max: 7.31
Current: 2.53

1.49
7.31
Quick Ratio 1.99
HOLX's Quick Ratio is ranked higher than
72% of the 275 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. HOLX: 1.99 )
HOLX' s 10-Year Quick Ratio Range
Min: 1.1   Max: 6.57
Current: 1.99

1.1
6.57

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.28
HOLX's Price/DCF (Projected) is ranked higher than
91% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. HOLX: 1.28 )
HOLX' s 10-Year Price/DCF (Projected) Range
Min: 0.41   Max: 5.71
Current: 1.28

0.41
5.71
Price/Median PS Value 1.08
HOLX's Price/Median PS Value is ranked higher than
76% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.20 vs. HOLX: 1.08 )
HOLX' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 1.7
Current: 1.08

0.16
1.7
Earnings Yield (Greenblatt) 2.60
HOLX's Earnings Yield (Greenblatt) is ranked higher than
70% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. HOLX: 2.60 )
HOLX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 7.9
Current: 2.6

0.8
7.9
Forward Rate of Return (Yacktman) 20.26
HOLX's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. HOLX: 20.26 )
HOLX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.6   Max: 76.7
Current: 20.26

-2.6
76.7

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:HO1.Germany
Hologic Inc was incorporated in Massachusetts in October 1985 and reincorporated in Delaware in March 1990. The Company is a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products focused on the healthcare needs of women. The Company's core business segments are focused on breast health, diagnostics, GYN surgical and skeletal health. The Company's breast health products include a broad portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, computer-aided detection (CAD), minimally invasive breast biopsy and tissue extraction devices, breast biopsy guidance systems, breast imaging comfort pads, and breast brachytherapy products. It has also developed a new breast imaging platform, Dimensions, which utilizes a new technology, tomosynthesis, to produce 3D images. The Company's diagnostic product offerings include the ThinPrep System used mainly for cytology applications, such as cervical cancer screening, and the Rapid Fetal Fibronectin Test for pre-term birth risk assessment. The Company's surgical product offerings include the NovaSure System, and the Adiana System. The NovaSure System enables physicians to treat women suffering from excessive menstrual bleeding in a minimally invasive manner. The Adiana System is a form of permanent female contraception intended as an alternative to tubal ligation. It sells and services its products through a combination of direct sales and service forces and a network of independent distributors and sales representatives. The Company's mammography and related products and subsystems compete with products offered by a number of competitors, including GE, Siemens, Philips, PlanMed, Agfa, Carestream Health, Fuji, IMS Giotto, Sectra and Toshiba. The manufacture, sale, lease and service of medical diagnostic and surgical devices and pharmaceutical products intended for commercial use are subject to extensive governmental regulation by the FDA in the United States and by a variety of regulatory agencies in other countries.
» More Articles for HOLX

Headlines

Articles On GuruFocus.com
Hologic Produces the First FDA-Approved 3D Mammography Platform Nov 26 2014 
Paul Tudor Jones Lives Up to Reputation As Active Trader in Third Quarter Nov 24 2014 
No More a Simple Distributor Sep 07 2014 
Carl Icahn Bets on Hologic; Should You? Aug 19 2014 
Weekly CFO Sells Highlight: Travelers Companies, Facebook, Hologic May 12 2014 
Weekly CEO Buys Highlight: HOLX, EPB, CLMS, IDTI, BYI Feb 17 2014 
GuruFocus Guru of the Year Carl Icahn's Top Fourth Quarter Holdings Feb 14 2014 
Weekly CEO Buys Highlight: KCG, OPK, HOLX, CLMS, TDC Feb 11 2014 
Guru of the Year 2013 – Carl Icahn Dec 31 2013 
Hologic’s Opportunity (Icahn Sees It. Do You?) Dec 16 2013 

More From Our Partners
Tracking Carl Icahn's Portfolio - Q3 2014 Update Nov 21 2014 - SEEKINGALPHA

More From Other Websites
HOLOGIC INC Financials Nov 27 2014
Hologic Produces the First FDA-Approved 3D Mammography Platform Nov 26 2014
Insider Trading Alert - SM, HOLX And EA Traded By Insiders Nov 24 2014
10-K for Hologic, Inc. Nov 22 2014
Hologic (HOLX) Advances in GYN Surgical with NovaSure Nov 20 2014
HOLOGIC INC Files SEC form 10-K, Annual Report Nov 20 2014
Hologic Launches Next-Generation NovaSure Global Endometrial Ablation System for the Treatment of... Nov 19 2014
Hologic Launches Next-Generation NovaSure Global Endometrial Ablation System for the Treatment of... Nov 19 2014
HOLOGIC INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Nov 10 2014
Hologic Beats Q4 Earnings, Sales as All Segments Gain Nov 07 2014
Hologic CEO: 3D will replace 2D mammography in 5 years Nov 06 2014
Hologic CEO: Unintended consequences of ACA tax Nov 06 2014
Hologic Announces Fourth Quarter Fiscal 2014 Operating Results Nov 05 2014
Hologic tops Street 4Q forecasts Nov 05 2014
Hologic tops Street 4Q forecasts Nov 05 2014
Hologic Inc Earnings Call scheduled for 4:30 pm ET today Nov 05 2014
HOLOGIC INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors... Nov 05 2014
Hologic Announces Fourth Quarter Fiscal 2014 Operating Results Nov 05 2014
Q4 2014 Hologic Inc Earnings Release - After Market Close Nov 05 2014
BTIG: Hologic To Gain From Higher 3D Mammogram Reimbursements Nov 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK